Case Studies Closed out

2020 IMR-SCD-301 ‘IMARA’ – A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease

By Kevin19/04/2024November 19th, 2024No Comments

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

Previous Post2018 GBT 034 – An Open-label Extension Study of Voxelotor (GBT 440) Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials (GBT440-034)
Next Post2021 GBT440-032 “HOPE Kids 2” – A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Paediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease